BioCryst Q3 2026 net income more than doubles to $37.92 million

Bitget2026/11/04 12:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioCryst Pharmaceuticals’ third-quarter 2026 net income more than doubled year-over-year to $37.92 million.
Total revenue rose 13% to $180.3 million, benefiting from CareMed’s initial ORLADEYO inventory build during the specialty pharmacy transition.
FDA approval in October expanded ORLADEYO oral pellets to patients aged 12 and older following the August pediatric launch.
Raised 2026 total revenue guidance to $715 million to $730 million, maintaining ORLADEYO revenue guidance at $625 million to $645 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040700PRIMZONEFULLFEED9869598) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioCryst Q3 2026 net income more than doubles to $37.92 million

You may also like

Crypto prices